Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Follow-Up Questions
Who is the CEO of Opus Genetics Inc?
Dr. George Magrath is the Chief Executive Officer of Opus Genetics Inc, joining the firm since 2023.
What is the price performance of IRD stock?
The current price of IRD is $1.48, it has decreased 0.6% in the last trading day.
What are the primary business themes or industries for Opus Genetics Inc?
Opus Genetics Inc belongs to Biotechnology industry and the sector is Health Care
What is Opus Genetics Inc market cap?
Opus Genetics Inc's current market cap is $93.3M
Is Opus Genetics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Opus Genetics Inc, including 1 strong buy, 6 buy, 1 hold, 0 sell, and 1 strong sell
